Pfizer (PFE) DIvidends Date & History

Key Takeaways

• Pfizer (PFE) offers a current dividend yield of approximately 6.2% based on an annual dividend of $1.72 per share.
• The company pays dividends quarterly at a rate of $0.43 per share.
• Pfizer has increased its dividend for 15 consecutive years, though recent annual growth has been modest at under 1%.
• The earnings payout ratio exceeds 200%, but free cash flow provides stronger coverage near 90%.
• The dividend yield stands notably higher than most large-cap pharmaceutical peers.
• Investors should monitor patent expirations and cash flow trends for long-term sustainability.

Dividend Overview

Pfizer (PFE) maintains a quarterly dividend policy, distributing $0.43 per share four times annually for a total of $1.72. At recent share prices near $27.46, this translates to a yield of roughly 6.2%. The most recent ex-dividend date was July 24, 2026, with payment on September 1, 2026. As a large pharmaceutical company, Pfizer qualifies as a high-yield dividend stock rather than a rapid dividend growth name. Its payout appeals primarily to income-focused investors seeking above-average returns in the healthcare sector.

Dividend History and Growth

Pfizer has raised its dividend annually for 15 consecutive years. The annual payout advanced from $1.20 in 2016 to the current $1.72 level. Increases have slowed in recent periods, with year-over-year growth of just 0.58% as the company held the quarterly rate at $0.43 following smaller prior adjustments. Payments remain consistent on a quarterly schedule without interruption, reflecting a long-standing commitment to returning capital to shareholders despite evolving revenue pressures from product cycles.

Dividend Sustainability and Payout Ratio

The earnings-based payout ratio stands elevated above 200%, indicating dividends exceed reported net income. However, free cash flow coverage appears more favorable, with recent estimates near 89-93%. Pfizer generates substantial operating cash flow that supports the current distribution, though elevated debt levels and upcoming patent expirations warrant ongoing attention. Management has signaled intent to maintain or gradually increase the dividend over time, supported by cost controls and pipeline development.

Dividend Compared to Industry Peers

Pfizer’s yield of approximately 6.2% exceeds most major pharmaceutical competitors. For context, Johnson & Johnson (JNJ) yields around 2.0%, Merck (MRK) near 2.3%, and AbbVie (ABBV) about 3.5%. Bristol-Myers Squibb (BMY) offers roughly 4.0%. While peers generally maintain lower payout ratios and steadier growth profiles, Pfizer’s elevated yield reflects a more income-oriented profile within the drug manufacturing sector.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the platform to explore opportunities tailored to dividend strategies.

Is This Stock Attractive for Dividend Investors?

Pfizer (PFE) may appeal to income-oriented investors comfortable with higher yields and moderate growth expectations. The stock suits those prioritizing current cash flow over rapid dividend increases, particularly within diversified portfolios. Conservative investors or those seeking lower payout ratios might prefer peers with stronger earnings coverage. Dividend growth investors could view the modest recent increases as a limitation, while long-term holders may value the established payment history and sector positioning. Overall suitability depends on individual risk tolerance, time horizon, and portfolio allocation goals. All investing involves risk, including potential loss of principal.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations